EBS FY 2024 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

FY 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.0B-0.5% YoY

Gross Profit

$375M36.0% margin

Operating Income

-$109M-10.4% margin

Net Income

-$191M-18.3% margin

EPS (Diluted)

$-3.60

Cash Flow

Operating Cash Flow

$59M

Free Cash Flow

$36M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$907M

Stockholders' Equity

$483M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.0B	$1.0B	-0.5%
Gross Profit	$375M	$360M	+4.3%
Operating Income	-$109M	-$726M	+85.0%
Net Income	-$191M	-$761M	+74.9%